NY-AIVF
22.6.2022 14:02:12 CEST | Business Wire | Press release
AiVF ®, developer of the first fully operational AI-based IVF software platform, announced today it has raised $25 million in a Series A round led by Insight Partners, a New York-based venture capital and private equity firm with participation from Adam Neumann’s Family Office, 166 2nd.
AiVF will use the funding to fuel adoption of the company’s AI platform, EMA™ in the United States and Europe, expand its work force and develop additional solutions to drive a new generation of digital fertility care.
“The dream of having a child has become more achievable for many because of AiVF’s entrepreneurial and technological prowess,” said Jeff Horing, Managing Director at Insight Partners. “We are strongly behind the expert leadership, the company strategy and are excited to be part of this leap forward in fertility care.”
The EMA platform provides an optimized end-to-end IVF journey to individuals seeking Assisted Reproductive Technologies for their family building. The advanced machine learning and computer vision algorithms developed by AiVF have the potential to shorten the time to pregnancy and increase IVF predictability and success rates.
Results of clinical research, performed with leading IVF clinics in Europe and the US, demonstrated that the EMA platform performs 50 times faster and is 48% more accurate than an embryologist in the clinic. After three years of extensive research and development, the platform is now operational across Europe and Asia. AiVF anticipates rapid deployment of its platform, as fertility clinics look to incorporate second generation IVF technologies to allow for improved IVF care.
“Our vision is to help individuals realize their dream to become families,” says Daniella Gilboa, AiVF co-founder, CEO, and clinical embryologist. “We are delivering innovative products to the market while enhancing the science of reproductive medicine to drive the next generation of fertility care.”
Since the first child was born by IVF 43 years ago, advances in fertility treatments have brought millions of children into the world. However, the technology is costly and outdated and is not able to keep up with the soaring demand. It is estimated that by the end of the 21st century, the number of IVF babies globally may reach over 1 billion.
“We can now leverage data to augment expertly trained clinicians, drive efficiencies and provide a new level of fertility care for all,” added Prof. Daniel Seidman, AiVF co-founder, chief medical officer, and an internationally renowned IVF specialist.
About AiVF
AiVF is a medical technology company empowering clinics with fertility intelligence. The company’s flagship product is an AI software platform that helps accelerate data-driven, automated and standardized processes for IVF patient care. The company partners with leading clinics around the globe to advance research and innovation in reproductive medicine. AiVF was founded by Daniella Gilboa and Prof Daniel Seidman, two Reproductive Medicine experts, in 2018 and is headquartered in Tel Aviv, Israel.
Follow us on Facebook , Instagram , LinkedIn , and Twitter , or visit AiVF.co for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2026 Results3.11.2026 22:30:00 CET | Press release
Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026Raising Low-End of Full Year 2026 Financial Guidance RangesRecently Completed $500M Share Repurchase AuthorizationFood Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027 IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modes
2026–2027 World Branding Awards Honours Global “Brand of the Year” Winners at Hampton Court Palace3.11.2026 21:00:00 CET | Press release
The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release
Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release
Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom